Henri Margot

Henri Margot

Auto-generated profile, based on publicly available information

Henri Margot

Genetic Medicine Service, Department of Diagnostics, Centre for Medical Genomics, Geneva University Hospitals, Geneva, Switzerland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CNCaroline Nava
Caroline Nava
BCBenjamin Cogne
Benjamin Cogne
ASAmandine Santini
Amandine Santini
ELElsa Leitão
Elsa Leitão
FLFrançois Lecoquierre
François Lecoquierre
CDChristel Depienne
Christel Depienne
The major spliceosome contains five small nuclear RNAs (snRNAs; U1, U2, U4, U5 and U6) essential for splicing. Variants in RNU4-2, encoding U4, cause a neurodevelopmental disorder called ReNU syndrome. We investigated de novo variants in 50 snRNA-encoding genes in a French cohort of 23,649 individuals with rare disorders and gathered additional cases through international collaborations. Altogether, we identified 145 previously unreported probands with (likely) pathogenic variants in RNU4-2 and 21 individuals with de novo and/or recurrent variants in RNU5B-1 and RNU5A-1, encoding U5. Pathogenic variants typically arose de novo on the maternal allele and cluster in regions critical for splicing. RNU4-2 variants mainly localize to two structures, the stem III and T-loop/quasi-pseudoknot, which position the U6 ACAGAGA box for 5′ splice site recognition and associate with different phenotypic severity. RNU4-2 variants result in specific defects in alternative 5′ splice site usage and methylation patterns (episignatures) that correlate with variant location and clinical severity. This study establishes RNU5B-1 as a neurodevelopmental disorder gene, suggests RNU5A-1 as a strong candidate and highlights the role of de novo variants in snRNAs.

1 January 2020 in Genetics in Medicine
Verified
Journal Article
Closed access
HMHenri Margot
Henri Margot
GBGuilaine Boursier
Guilaine Boursier
CDClaire Duflos
Claire Duflos
ESElodie Sanchez
Elodie Sanchez
JAJeanne Amiel
Jeanne Amiel
DGDavid Geneviève
David Geneviève

8 October 2024 in medRxiv
Verified
Preprint
Open access
PDF file
CNCaroline Nava
Caroline Nava
BCBenjamin Cogne
Benjamin Cogne
ASAmandine Santini
Amandine Santini
ELElsa Leitão
Elsa Leitão
FLFrançois Lecoquierre
François Lecoquierre
CDChristel Depienne
Christel Depienne
Variants in RNU4-2 , encoding the small nuclear RNA (snRNA) U4, were recently identified as a major cause of neurodevelopmental disorders (ReNU syndrome). Here, we investigated de novo variants in 50 snRNAs in a French cohort of 23,649 individuals with rare disorders and collected data of additional patients through an international collaboration. Altogether, we identified 133 probands with pathogenic or likely pathogenic variants in RNU4-2 and 15 individuals with de novo and/or recurrent variants in constrained regions of RNU5B-1 , one of five genes encoding U5. These variants cluster in evolutionarily conserved regions of U4 and U5 essential for splicing. RNU4-2 variants affecting stem III are associated with milder phenotypes than those in the T-loop (quasi-pseudoknot). Phaseable variants associated with severe phenotypes occurred on the maternal allele. Individuals with RNU4-2 variants show specific defects in alternative 5’ splice site usage, correlating with variant location and clinical severity. Additionally, we report an episignature associated with severe ReNU syndrome. This study further highlights the importance of de novo variants in snRNAs and establishes RNU5B-1 as a new neurodevelopmental disorder gene.

25 March 2026 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
Quentin SabbaghQuentin Sabbagh
Quentin Sabbagh
CCCamille Cenni
Camille Cenni
SHSadegheh Haghshenas
Sadegheh Haghshenas
JAJean-Luc Alessandri
Jean-Luc Alessandri
MBMads Bak
Mads Bak
DGDavid Geneviève
David Geneviève

2 August 2016 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
HMHenri Margot
Henri Margot
DGDavid Geneviève
David Geneviève
VGVincent Gatinois
Vincent Gatinois
BABenoit Arveiler
Benoit Arveiler
SMSébastien Moutton
Sébastien Moutton
DLDidier Lacombe
Didier Lacombe

2 October 2024 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
HMHenri Margot
Henri Margot
NJNatalie Jones
Natalie Jones
TMThibaut Matis
Thibaut Matis
DBDominique Bonneau
Dominique Bonneau
TBTiffany Busa
Tiffany Busa
FNFrench Cowden Disease Network
French Cowden Disease Network
Background: PTEN hamartoma tumour syndrome (PHTS) encompasses distinct syndromes, including Cowden syndrome resulting from PTEN pathogenic variants. Missense variants account for 30% of PHTS cases, but their classification remains challenging. To address these difficulties, guidelines were published by the Clinical Genome Resource PTEN Variant Curation Expert Panel. Methods: Between 2010 and 2020, the Bergonie Institute reference laboratory identified 76 different non-truncating PTEN variants in 166 patients, 17 of which have not previously been reported. Variants were initially classified following the current guidelines. Subsequently, a new classification method was developed based on four main criteria: functional exploration, phenotypic features and familial segregation, in silico modelling, and allelic frequency. Results: This new method of classification is more discriminative and reclassifies 25 variants, including 8 variants of unknown significance. Conclusion: This report proposes a revision of the current PTEN variant classification criteria which at present rely on functional tests evaluating only the phosphatase activity of PTEN and apply a particularly stringent clinical PHTS score.The classification of non-truncating variants of PTEN is facilitated by taking into consideration protein stability for variants with intact phosphatase activity, clinical and segregation criteria adapted to the phenotypic variability of PHTS and by specifying the allelic frequency of variants in the general population. This novel method of classification remains to be validated in a prospective cohort.